Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
Jingxuan Wei, Kai Xu, Yingtao Lin, Qiang Liu, Chongchong Zhou, Pei Zhang, Rui Ma, Mengdie Zhang, Lingli Zhang, Xin Li
Topics & Concepts
MedicineSorafenibHepatocellular carcinomaOncologyInternal medicineChinaFirst line therapyPolitical scienceLawHepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers